Home
Series of Journals
Literature
Latest literature
Popular literature
About us
Intro
Organizational structure
Job Responsibilities
Copyright
Contact us
The title
The title
The keywords
The author
Wuhan University
Zhongnan Hospital of Wuhan University
Center for Evidence-Based and Translational Medicine of Wuhan University
Home
Results
The title
The title
The keywords
The author
A total of
6
result was found. Results that relate to
Camrelizumab
A case report of immunotherapy-related breast reactive capillary endothelial proliferation
Published on
New Medicine
2023,33(1):74-77.
5241 times
1760 times
Chen JIE
Jing YU
Ru-Meng LI
Jun GONG
Cong-Hua XIE
Reactive capillary endothelial proliferation
Breast
Immunotherapy
Camrelizumab
Details
Pharmaceutical care of rare immune-related abducens nerve adverse events induced by camrelizumab
Published on
Chinese Journal of Pharmacoepidemiology
2023,32(11):1305-1310.
6325 times
1711 times
Ren-Pei LIANG
Guan LIN
Zhang-Chao LAI
Camrelizumab
Abducens nerve palsy
Adverse drug reaction
Pharmaceutical care
Details
Evaluation of the efficacy and safety of Camrelizumab combined with Shenqi Fuzheng injection in the treatment of advanced non-squamous non-small cell lung cancer patients
Published on
Frontiers in Pharmaceutical Sciences
2023,36(11):241-248.
5884 times
1237 times
Wen-Ze SUN
Ying-Bing ZHANG
Lin WANG
Advanced non-squamous non-small cell cancer
Camrelizumab
Shenqi Fuzheng injection
Details
Efficacy and safety of camrelizumab combined with apatinib in the treatment of triple-negative breast cancer: a Meta-analysis and systematic review
Published on
Chinese Journal of Pharmacoepidemiology
2024,33(10):1137-1146.
7587 times
1427 times
NIU Zhaofeng
ZHAI Yanghai
GENG Rui
Camrelizumab
Apatinib
Triple-negative breast cancer
Meta-analysis
Systematic review
Details
Literature analysis of adverse reactions to multiple organ injury induced by camrelizumab
Published on
Frontiers in Pharmaceutical Sciences
2024,28(4):648-656.
8588 times
1008 times
ZHANG Yang
SU Wenyang
GAO Yue
Camrelizumab
Multiple organ injury
Adverse reactions
Literature system analysis
Immunotherapy
Programmed death protein 1
Details
Clinical pharmacist participated in a case study of a severe immune-related cholestatic liver injury case induced by camrelizumab
Published on
Chinese Journal of Pharmacoepidemiology
2025,34(3):341-345.
7833 times
986 times
YUWEN Lixia
HE Yunhao
YUAN Yaohui
Clinical pharmacist
Camrelizumab
Liver injury
Cholestatic
Immunotherapy
Details